Reporting from the 2021 AACR Virtual Annual Meeting, Vivek Subbiah comments on promising therapeutic options in previously treated populations presenting actionable oncogenic drivers: selpercatinib in solid tumours other than lung or thyroid cancers with RET fusions, futibatinib in intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements. He also discusses the results of dabrafenib plus trametinib combination in high-grade and low-grade glioma with BRAF V600E mutation.
These results emphasise the importance of broad-base genomic profiling to identify potential actionable targets and the patients who could benefit from a precision medicine approach.
- CT011 - Efficacy and Safety of Selpercatinib in RET Fusion-Positive Cancers Other than Lung or Thyroid Cancers
- CT010 - Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements
- CT025 - Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG)
This video was supported with an educational grant from Bayer and Daiichi Sankyo.
The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.